CTLA4 and melanoma: Thus, we reviewed publicly available exome-sequencing data from patients with melanoma undergoing CTLA-4 or PD-1 blockade therapy to investigate potential correlations between PRKDC levels and response to checkpoint therapy (2, 33, 34).